James Lu
Overview
Explore the profile of James Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
658
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levy M, Chilunda V, Heaton P, McKeen D, Goldman J, Davis R, et al.
Front Immunol
. 2025 Mar;
16:1470609.
PMID: 40034704
As part of a multi-state viral genomic surveillance program, we conducted a case-only analysis to evaluate the effectiveness of XBB.1.5-adapated mRNA vaccines in preventing severe illness among individuals with medically...
2.
Bandel L, Vierkant R, Kruisselbrink T, Bublitz M, Wilson T, Armasu S, et al.
Mayo Clin Proc
. 2024 Dec;
PMID: 39625429
Objective: To execute a large-scale, decentralized, clinical-grade whole exome sequencing study, coined Tapestry, for clinical practice, research discovery, and genomic education. Patients And Methods: Between July 1, 2020, and May...
3.
Vora B, Jindal A, Velasquez E, Lu J, Wu B
Clin Transl Sci
. 2024 Nov;
17(11):e70077.
PMID: 39558509
The increase in the availability of real-world data (RWD), in combination with advances in machine learning (ML) methods, provides a unique opportunity for the integration of the two to explore...
4.
Levy M, Chilunda V, Davis R, Heaton P, Pawloski P, Goldman J, et al.
J Infect Dis
. 2024 Jul;
230(5):1197-1201.
PMID: 39028664
Within a multistate viral genomic surveillance program, we evaluated whether proportions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections attributed to the JN.1 variant and to XBB-lineage variants (including...
5.
Velasquez E, Kassir N, Cheeti S, Kuruvilla D, Sane R, Dang S, et al.
Front Artif Intell
. 2024 Jun;
7:1412865.
PMID: 38919267
In oncology drug development, tumor dynamics modeling is widely applied to predict patients' overall survival (OS) via parametric models. However, the current modeling paradigm, which assumes a disease-specific link between...
6.
Bender B, Li C, Marchand M, Turner D, Li F, Vadhavkar S, et al.
Clin Transl Sci
. 2024 May;
17(6):e13825.
PMID: 38808543
Mosunetuzumab (Mosun) is a CD20xCD3 T-cell engaging bispecific antibody that redirects T cells to eliminate malignant B cells. The approved step-up dose regimen of 1/2/60/30 mg IV is designed to...
7.
Liu G, Brooks L, Canty J, Lu D, Jin J, Lu J
CPT Pharmacometrics Syst Pharmacol
. 2024 Mar;
13(5):870-879.
PMID: 38465417
Noncompartmental analysis (NCA) is a model-independent approach for assessing pharmacokinetics (PKs). Although the existing NCA algorithms are very well-established and widely utilized, they suffer from low accuracies in the setting...
8.
Levy M, Burrows E, Chilunda V, Pawloski P, Heaton P, Grzymski J, et al.
Clin Infect Dis
. 2024 Jan;
78(6):1531-1535.
PMID: 38170452
Within a multistate clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among nonhospitalized patients with SARS-CoV-2 with risk factors for severe COVID-19. Among 3247 adults, only...
9.
Naik K, Goyal R, Foschini L, Chak C, Thielscher C, Zhu H, et al.
Clin Pharmacol Ther
. 2023 Dec;
115(4):673-686.
PMID: 38103204
Technological innovations, such as artificial intelligence (AI) and machine learning (ML), have the potential to expedite the goal of precision medicine, especially when combined with increased capacity for voluminous data...
10.
Laurie M, Lu J
NPJ Syst Biol Appl
. 2023 Nov;
9(1):58.
PMID: 37980358
While tumor dynamic modeling has been widely applied to support the development of oncology drugs, there remains a need to increase predictivity, enable personalized therapy, and improve decision-making. We propose...